



#3

FORM 1449°		Docket Number 30436.57USU1	Application Number 09/865,321
 <p>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</p> <p>(Use several sheets if necessary)</p>		Applicant Robert J. Peach et al.	
		Filing Date May 23, 2001	Group Art Unit Not yet known


U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
24/2	5,637,481 (Exhibit 1)	6/10/97	Ledbetter et al.	X	X	9/13/93
	5,773,253 (Exhibit 2)	6/30/98	Linsley et al.			7/21/95
	5,844,095 (Exhibit 3)	12/1/98	Linsley et al.			1/18/95
	5,851,795 (Exhibit 4)	12/22/98	Linsley et al.			6/2/96
	5,885,579 (Exhibit 5)	3/23/99	Linsley et al.			7/8/97
	5,885,796 (Exhibit 6)	3/23/99	Linsley et al.			7/8/97
	5,958,403 (Exhibit 7)	9/28/99	Strom et al.			7/11/94
	5,968,510 (Exhibit 8)	10/19/99	Linsley et al.			10/4/96
24/2	5,977,318 (Exhibit 9)	11/2/99	Linsley et al.			6/7/95

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
24/2	EP 757,099 (Exhibit 10)	5/2/97	Europe	X	X		X
	WO 93/00,431 (Exhibit 11)	1/7/93	PCT				X
	WO 95/01,994 (Exhibit 12)	1/19/95	PCT				X
	WO 95/33,770 (Exhibit 13)	12/14/95	PCT				X
	WO 97/28,267 (Exhibit 14)	8/7/97	PCT				X
	WO 97/37,687 (Exhibit 15)	10/16/97	PCT				X
	WO 97/47,732 (Exhibit 16)	12/18/97	PCT				X
	WO 98/31,820 (Exhibit 17)	7/23/98	PCT				X
	WO 98/33,513 (Exhibit 18)	8/6/98	PCT				X
	WO 99/29,883 (Exhibit 19)	6/17/99	PCT				X
	WO 99/47,558 (Exhibit 20)	9/23/99	PCT				X
	WO 99/49,734 (Exhibit 21)	10/7/99	PCT				X
	WO 99/51,275 (Exhibit 22)	10/14/99	PCT				X
24/2	WO 99/57,266 (Exhibit 23)	11/11/99	PCT				X

EXAMINER 	DATE CONSIDERED 11/20/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)


Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449°  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit Not yet known

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
212	Turka et al. (1992), Proc. Natl. Acad. Sci USA 89:11102-11105 (Exhibit 24)
	Lenschow et al. (1992) Science 257: 789-792 (Exhibit 25)
	Linsley et al. (1992) Science 257: 792-795 (Exhibit 26)
	Linsley et al. (1992) J. Exp. Med. 176:1595-1604 (Exhibit 27)
	Tan et al. (1993) J. Exp. Med. 177:165-173 (Exhibit 28)
	Linsley et al. (1994) Immunity 1:793-801 (Exhibit 29)
	Peach et al. (1994) J. Exp. Med. 180:2049-2058 (Exhibit 30)
	Steurer et al. (1995) J. Immunol. 155:1165-1174. (Exhibit 31)
	Fargeas et al. (1995) J. Exp. Med. 182:667-675. (Exhibit 32)
	Peach et al. (1995) J. Biol. Chem. 270(36): 21181-21187. (Exhibit 33)
	Alegre et al. (1995) Dig. Dis. Sci. 40(1):58-64. (Exhibit 34)
	Guo et al. (1995) J. Exp. Med. 181:1345-1355. (Exhibit 35)
	Rattis et al. (1996) Eur. J. Immunol. 26:449-453. (Exhibit 36)
	Murakami et al. (1996) Proc. Nat. Acad. Sci. USA 93:7838-7842. (Exhibit 37)
	Morton et al. (1996) J. Immunol. Feb 1; 156:1047-1054. (Exhibit 38)
	Parsons et al (1996) Immunogenetics 43:388-391. (Exhibit 39)
	Oaks et al (1996) Immunogenetics 43:172-174. (Exhibit 40)
	Peach et al. (1995) Methods 8:116-123 (Exhibit 41)
	Harris et al. (1997) J. Exp. Med. 185:177-182 (Exhibit 42)
	Greene et al. (1996) J. Bio. Chem. 271:26762-26771 (Exhibit 43)
	van der Merwe et al. (1997) J. Exper. Med. 185:393-403. (Exhibit 44)
	Gallon et al. (1997) J. Immunol. 159:4212-4216. (Exhibit 45)
	Höllsberg et al. (1997) J Immunol. 159:4799-4805. (Exhibit 46)
	Bajorath et al. (1997) J Mol Graphics and Modeling 15:135-139. (Exhibit 47)
	Greenwald et al. (1997) J Immunol. 158:4088-4096. (Exhibit 48)
	Metzler et al. (1997) Nat Struc Bio 4:527-531. (Exhibit 49)
	Rajesh et al. (1998) Pharm Sci Supplement S 535. (Exhibit 50) Duphutz
	Nuttall et al. (1999) Proteins: Structure, Functions, and Genetics 36:217-227. (Exhibit 51)
212	Pearson et al. (2000) Transplantation 69:S-123. (Exhibit 52) (Abstract #44)
EXAMINER	DATE CONSIDERED 1/5/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

30436.57USU1

Application Number

09/865,321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

Not yet known

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

212

Reynolds et al. (2000) J Clinical Investigation 105:643-651. (Exhibit 53)

Cinek et al. (2000) J Immunol. 164:5-8. (Exhibit 54)

Masteller et al. (2000) J Immunol. 164:5319-5327. (Exhibit 55)

Hufton et al. (2000) FEBS Letters 475:225-231. (Exhibit 56)

212

Larsen, Christian P. (2000) LEA29Y 20 Pages of Slides (Exhibit 57)

EXAMINER

DATE CONSIDERED

1/15/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



(Use several sheets if necessary)

1646

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Dock 1 Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
						YES	NO
<i>JNR</i>	WO 95/33770 (Exhibit 105)	December 14, 1995	PCT				X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>JNR</i>	Linsley, et al., 1991, <i>J. Exp. Med.</i> "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. (Exhibit 65)						
	Gimmi, et al., 1993, <i>Proc. Natl. Acad. Sci. USA</i> "Human T-Cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation" 90:6586-6590. (Exhibit 66)						
	Azuma et al., 1993 <i>Nature</i> "B70 antigen is a second ligand for CTLA-4 and CD28" 366:76-79. (Exhibit 67)						
	Ronchese et al., 1994 <i>J. Exp. Med.</i> "Mice Transgenic for a Soluble Form of Murine CTLA-4 Show Enhanced Expansion of Antigen-specific CD4 T Cells and Defective Antibody production In Vivo" 179:809-817. (Exhibit 68)						
	Griggs et al., 1996 <i>J. Exp. Med.</i> "The Relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathogenic Acquisition of Self-reactive T Cells" 183:801-810. (Exhibit 69)						
	Linsley et al., <i>J. Exp. Med.</i> "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. (Exhibit 70)						
	Verwilghen et al., 1994 <i>J. Immunol.</i> Expression of Functional B& and CTLA4 on Rheumatoid Synovial T Cells" 153:1378-1385. (Exhibit 71)						
	Blazar et al., 1994 <i>Blood</i> "In Vivo Blockade of CD28/CTLA4: Interaction With CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice" 83:3815-3825. (Exhibit 72)						
	Finck et al., <i>Science</i> "Treatment of Murine lupus with CTLA4Ig" 265:1225-1227. (Exhibit 73)						
	Perrin et al., 1995 <i>J. Immunol.</i> "Role of B7:CD28/CTLA4 in the Induction of Chronic Relapsing Experimental Allergic Encephalomyelitis" 154:1481-1490. (Exhibit 74)						
	Pearson et al., 1994 <i>Transplantation</i> "Transplantation Tolerance Induced By CTLA4-Ig" 57:1701-1706. (Exhibit 75)						
	Baliga et al., 1994 <i>Transplantation</i> "CTLA4Ig PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED IMMUNITY" 58:1082-1090. (Exhibit 76)						
<i>JNR</i>	Tepper et al., 1994 <i>Transplantation Proceedings</i> "Tolerance Induction by soluble CTLA4 in a Mouse Skin Transplant Model" 26:3151-3154. (Exhibit 77)						

EXAMINER <i>J. R. [Signature]</i>	DATE CONSIDERED 1/15/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449*

Docket Number

Application Number

30436.57USU1

09/865,321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DIV2	Perico et al., 1995 <i>Kidney International</i> "Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig" 47:241-246. (Exhibit 78)
	Finck et al., 1994 <i>Arthritis and Rheumatism</i> "Effects of CTLA4Ig in murine lupus" 37:S222. (Exhibit 79) Abstract # 375
	Nishikawa et al., 1994 <i>Eur J. Immunol.</i> "Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis" 24:1249-1254. (Exhibit 80)
	Wallace et al., 1994 <i>Transplantation</i> "CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers" 58:602-610. (Exhibit 81)
	Damle et al., <i>J. Immunol.</i> "Costimulation of T Lymphocytes with integrin Ligands intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, a Second Receptor for B7" 152:2686-2697. (Exhibit 82)
	Milich, et al., 1994 <i>J. Immunol</i> "Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model," 153:429-435. (Exhibit 83)
	Webb, et al., 1996 <i>Eur J. Immunol</i> "Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2," 26:2320-2328. (Exhibit 84)
	Van Oosterhout, et al., 1997 <i>Am.J.Respir. Cell Mol. Biol.</i> "Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of allergic Asthma," 17:386-392. (Exhibit 85)
	Abams et al., 1999 <i>J-Clin-Invest</i> "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 103:1243-1252. (Exhibit 86)
	Ibrahim, et al., 1996 <i>Blood</i> "CTLA4Ig Inhibits Alloantibody Responses to Repeated Blood Transfusions," 88:4594-4600. (Exhibit 87)
	Lenschow, et al., 1995 <i>J Exp Med</i> "Differential Effects of anti-B7-1 and Anti-b&-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse," 181:1145-1155. (Exhibit 88)
	Lenschow, et al., 1992 <i>Science</i> "Long-Term Survival of Xenogeneic Pancreatic islet Grafts Induced by CTLA4Ig," 257:789-792. (Exhibit 89)
	Blazar, et al., 1994 <i>Blood</i> "In Vivo Blockade of CD28/CTLA4:B7/BB1 Interaction with CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice," 83:3815-3825. (Exhibit 90) Duplicate
	Griggs, et al., 1996 <i>J Exp Med</i> "The relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathogenic Acquisition of Self-reactive T-Cells," 183:801-810. (Exhibit 91) Duplicate
	Sayegh, 1999 <i>J Clin Invest</i> "Finally, CTLA4Ig graduates to the clinic," 103:1223-1225. (Exhibit 92)
	Abrams, et al., 1999 <i>J Clin Invest</i> "CTLA4Ig-mediated blockade of T-cell costimulation I patients with psoriasis vulgaris," 103:1243-1252. (Exhibit 93)
	Wolfe, 1995 <i>Bailliere's Clinical Rheumatology</i> "The epidemiology of drug treatment failure in rheumatoid arthritis," 9:619-632. (Exhibit 94)
DIV2	Hochberg, et al., 1990 <i>Epidemiologic Reviews</i> "Epidemiology of Rheumatoid Arthritis: Update," 12:247-252. (Exhibit 95)

EXAMINER

DATE CONSIDERED

11/15/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*

Docket Number

Application Number

30436.57USU1

09/865,321

Applicant

Robert J. Peach et al.

Filing Date


May 23, 2001

Group Art Unit

1646

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

mc		Spector, 1990 <i>Epidemiology of Rheumatic Disease</i> "Rheumatoid Arthritis," 16:513-537. (Exhibit 96)
		Liu MF, Kohsaka H Sakurai H, Azuma m Okumura K Saito I, Miyasaka N, 1996. "The presence of costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid arthritis synovium" <i>Arthritis-Rheum.</i> Jan; 39(1): 110-4. (Exhibit 97)
		Sfikakis PP, Via CS. 1997 "Expression of CD28, CTLA4, CD80, CD86 molecules in-patients with autoimmune rheumatic diseases: implications for immunotherapy". <i>Clin-Immunol-Immunopathol.</i> Jun; 83(3): 195-8. (Exhibit 98)
		Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA, 1995. <i>J. Exp. Med.</i> "CD28-B7 blockade after all antigenic challenge in vivo inhibits Th1 cytokines but spares Th2". 181: 1869-1874. (Exhibit 99)
		Racusen LC; et. al. 1999. "The Baniff 97 working classification of renal allograft pathology". <i>Kidney-Int.</i> 55(2): 713- 723. (Exhibit 100)
		Parkin D, Jacoby A, McNamee P, 2000. "Treatment of multiple sclerosis with interferon β : an appraisal of cost-effectiveness and quality of life" <i>J Neurol Neurosurg Psychiatry</i> ; 68: 144-149. (Exhibit 101)
		Nortvedt MW, Riise T, Myhr KM, and Nyland HI, 1999. "Quality of life in multiple sclerosis: measuring the disease effects more broadly" <i>Neurology</i> ; 53(5): 1098-1103 (Exhibit 102)
		Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP, 1994. "Transplantation tolerance induced by CTLA4-Ig. <i>Transplantation</i> , 57:1701-1706. (Exhibit 103)
		Liao HX, Haynes BF, 1995. "Role of adhesion molecules in the pathogenesis of rheumatoid arthritis" <i>Rheum-Dis-Clin-Noth-Am.</i> Aug; 21(3): 715-40. (Exhibit 104)
		Thomas R, Quinn C. 1996. "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" <i>J-Immunol.</i> Apr 15; 156(8): 3074-86. (Exhibit 106)
		Verhoeven-AC; Boers-M; Tugwell-P, 1998. "Combination therapy in rheumatoid arthritis: updated systematic review" <i>Br-J-Rheumatol.</i> Jun;37 (6): 612-619 (Exhibit 107)
		Schiff M, 1997. "Emerging treatments for rheumatoid arthritis" <i>Am-J-Med.</i> Jan 27; 102 (1A): 11S-15S (Exhibit 108)
		Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND, 1996. "Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue" <i>Br-J-Rheumatol.</i> Jan; 35(1): 33-7 (Exhibit 109)
		Ranheim Ea, Kipps Tj, 1994. "Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis" <i>Arthritis-Rheum.</i> Nov;37 (11): 1637-1647 (Exhibit 110)
		Freeman GJ, Gribben JG, Boussiotis VA, et. al. 1993. "Cloning of B7-2: a CTLA-4 counter receptor that costimulates human T cell proliferation" <i>Science</i> , 262: 909-911. (Exhibit 111)
		Baliga P, Chavin KD, Qin L, et. al. "CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity" <i>Transplantation</i> , 58(10): 1082-1090. (Exhibit 112)
		Thomas R, Quinn C, 1996 "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" <i>J-Immunol.</i> Apr 15;156(8): 3074-86 (Exhibit 113)

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#12

Sh et 12

FORM 1449*		Docket Number 30436.57USU1	Application Number 09/865,321
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Applicant Robert J. Peach et al.	
		Filing Date May 23, 2001	Group Art Unit 1646


 MAY 08 2002
 TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE	
JR	5,434,131 (Exhibit 137)	7/18/95	Linsley et al.			5/26/93	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
						YES	NO
JR	WO 02/02638 A2 (Exhibit 138)	1/10/02	PCT				X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
JR		Becker, J.C., March 8, 2001, Abstract and of Presentation of "A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA29Y administration intravenously to subjects with rheumatoid arthritis," presented at American College of Rheumatology Conference: "2001 Innovative Therapies in Autoimmune Diseases," San Francisco, California (Exhibit 114)					
		Aruffo, S., March 27, 2000, Presentation of "Approaches to Immune Regulation" at BIO 2000 in Boston, Mass. (Exhibit 115)					
		Abrams, et al., September 4, 2000, <i>J.Exp.Med.</i> "Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte- associated Antigen 4-Immunoglobulin (CTLA4Ig) Reverse the Cellular Pathology of Psoriatic plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells," 192:681-693. (Exhibit 116)					
		Srinivas, N.R. et al., December 1, 1995, <i>J.Pharmaceutical Sciences</i> "Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMA-188667), a Novel Immunosuppressive Agent, in Monkeys following Multiple Doses," 85:1-4. (Exhibit 117)					
		Gandhi, et al., November 18, 1998, Abstract and Presentation of <i>PharmSci Supplement</i> "Physical and Chemical Characterization of BMS-224818, A Recombinant Fusion Protein," in San Francisco, Ca. (Exhibit 118) page 5-535					
		Flesher, A.R., April 15, 1999, <i>Biological Process Sciences</i> Presentation of "Transgenic Production, A Comparative Study" at Bio 99 in Seattle, Washington. (Exhibit 119)					
		Greve, K.F., May 9, 1996, <i>J Chromatography</i> "Capillary electrophoretic examination of underivatized oligosaccharide mixtures released from immunoglobulin G antibodies and CTLA4Ig fusion protein," 749:237-245. (Exhibit 120)					
JR		Srinivas, N.R., April 8, 1997, <i>Pharmaceutical Research</i> "Assessment of Dose Proportionality, Absolute Bioavailability, and Immunogenicity Response of CTLA4Ig (BMS-188667), a Novel Immunosuppressive Agent, Following Subcutaneous and Intravenous Administration to Rats," 14:911-916. (Exhibit 121)					

EXAMINER	DATE CONSIDERED 11/5/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office ; U.S. DEPARTMENT OF COMMERCE

RECEIVED

Sheet 2

TECH CENTER 1600/2900

MAY 08 2002

FORM 1449*	Docket Number 30436.57USU1		Application Number 09/865,321
	Applicant Robert J. Peach et al.		
	Filing Date May 23, 2001	Group Art Unit 1646	
	INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		


MAY 06 2002
PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

2	Weiner, R.S., November 6-10, 1994, Abstract and Presentation of "Validation and PK Application of a Double Antibody Sandwich Enzyme Immunoassay For the Quantitation of Human CTLA4g Fusion Protein (BMS-188667) In Mouse Serum," (Exhibit 122)
	Weiner, R.S., June 6, 1996, <i>J Pharmaceutical and Biomedical Analysis</i> "A sensitive enzyme immunoassay for the quantitation of human CTLA4g fusion protien in mouse serum: pharmacokinetic application to optimizing cell line selection," 15:571-579. (Exhibit 123)
	Warner, G.I. et al., March 16-22, 1995, Abstract and Presentation of "Bioactivity of BMS-188667 (CTLA4g) in Cynomolgus Monkeys," in Seattle, Washington. (Exhibit 124)
	Weiner, R.S., March 1, 2000, Abstract and Presentation of "Industrial Perspectives of Primary Analytical Tools for Macromaloeucles- Principles and Applications with Examples." (Exhibit 125)
	Weiner, R.S., November 1995 Abstract and Presentation of "Validation of an Enzyme Immunoassay For The Quantition of Human CTLA4g Fusion Protein In Human Serum," in Miami, Florida. (Exhibit 126)
	Weiner, R.S., November 1995 Abstract and Presentation of "Automation and Validation of An EIA For Quantition of Human CTLA4g In Monkey Serum," in Miami, Florida. (Exhibit 127)
	Webb, L.M.C. et al., July 23, 1996 <i>Eur J Immunol</i> "Prevention and amelioration of collagen-induced arthritis by blocade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2" 26:2320-2328. (Exhibit 128)
	Knoerzer, et al., May 5, 1995, <i>J Clin. Invest</i> "Collagen-induced Arthritis in the BB Rat Prevention of Disease by Treatment with CTLA4Ig" 96:987-993. (Exhibit 129)
	Larsen, et al., April 27, 2000, Abstract of "Prolongation of Renal Allograft Survival with Blockade of the CD28 Pathway Using A Novel Mutant CTLA4-Ig Fusion Protein In Non-Human Primates," in <i>Transplantation</i> , 69(8):#44, p. S123, Chicago, Il. (Exhibit 130)
	Larsen, et al., May 13-17, 2000, A Presentation of "Prolongation of Renal Allograft Survival With Blockade of the CD28 Pathway Using A Novel Mutant CTLA4-Ig Protein In Nonhuman Primates" at the American Society of Transplantation Meeting in Chicago, Il. (Exhibit 131)
	Larsen, Aug. 27-Sept.1, 2000, A Presentation of "Manipulation of Costimulatory Pathways: Targeting CD80 and CD86" at the XVII congress of the Transplantation Society in Rome, Italy. (Exhibit 132)
	Larsen, March 3-4, 2000, A Presentation of "Costimulation blockade: progress toward clinical application" at Canadian Society of Transplantation Annual Scientific meeting in Mont Tremblant, Quebec, Canada. (Exhibit 133)
	Larsen, Jan. 13-17, 2000, A Presentation of "Costimulation blockade: Progress toward clinical application" at the American Society of Transplantation Meeting in Las Croabas, Puerto Rico. (Exhibit 134)
	Hathcock, et al., August 30, 1993 <i>Science</i> "Identification of an Alternative CTLA-4 Ligand Costimulatory for t Cell Activation," 262:905-911. (Exhibit 135)
other	Sfikakis, et al., November 29, 1994 <i>Arthritis & Rheumatism</i> "CD28 Expression On T Cell Subsets in Vivo And CD28-Mediated T Cell Response In Vitro In Patients With Rheumatoid Arthritis," 38:649-654. (Exhibit 136)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 1/20/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE




FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
RECEIVED JUN 19 2002 TECH CENTER 1600/2000			Lakkis, Fadi G., et al., "Blocking the CD28-B7 T Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4 ¹ ," <i>The Journal of Immunology</i> , 1997, 158:2443-2448. (Exhibit 139)				
			Pearson, Thomas C., et al., "ANALYSIS OF THE B7 COSTIMULATORY PATHWAY IN ALLOGRAFT REJECTION ¹ ," <i>Transplantation</i> , 1997, 63:1463-1469. (Exhibit 140)				
			Pearson, Thomas C., et al., "TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig ¹ ," <i>Transplantation</i> , 1994, 57:1701-1706. (Exhibit 141)				
			Alexander, Diane Z., "ANALYSIS OF A FUNCTIONAL ROLE FOR CHIMERISM IN CTLA4-Ig PLUS BONE MARROW-TREATED CARDIAC ALLOGRAFT RECIPIENTS," <i>Transplantation</i> , 1994, 91:416-418. (Exhibit 142)				
			Larsen, Christian P., et al., "CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOFRAFT REJECTION" <i>Transplantation</i> , 1996, 61:4-9. (Exhibit 143)				
			Pearson, Thomas C., et al., "CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESONSIVENESS IN THE MURINE MODEL", <i>Transplantation</i> , 1996, 61:997-1004. (Exhibit 144)				
			Weber, C.J., et al., "CTLA4-Ig Prolongs Survival of Microencapsulated Rabbit Islet Xenografts in Spontaneously Diabetic Nod Mice," <i>Transplantation Proceedings</i> , 1996, 28:821-823. (Exhibit 145)				
			Alexander, D.Z., et al., "Analysis of effector mechanisms in murine cardiac allograft rejection," <i>Transplantation Immunology</i> , 1996, 4:46-48. (Exhibit 146)				
			Larsen, Christian P., et al., "Long-Term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," <i>Nature</i> , 1996, 381:434-438. (Exhibit 147)				
			Elwood, Eric T., et al., "Microchimerism and rejection in clinical transplantation," <i>The Lancet</i> , 1997, 349:1358-1360. (Exhibit 148)				
			Larsen, Christian P., and Thomas C. Pearson., "The CD40 pathway in allograft rejection, acceptance, and tolerance," <i>Transplantation</i> , 1997, 9:641-647. (Exhibit 149)				
			Konieczny, Bogumila T., et al., "IFN- γ Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Constimulation Pathways ¹ ," <i>The Journal of Immunology</i> , 1998, 160:2059-2064. (Exhibit 150)				

EXAMINER <i>Jph</i>	DATE CONSIDERED 1/20/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED JUN 19 2002 TECH CENTER 1610/2300	212	Elwood, Eric T., et al., "PROLONGED ACCEPTANCE OF CONCORDANT AND DISCORDANT XENOGRAFTS WITH COMBINED CD40 AND CD28 PATHWAY BLOCKADE ¹ ," <i>Transplantation</i> , 1998,65:1422-1428. (Exhibit 151)
		Niimi, Masanori, et al., "The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness in Vivo ¹ ," <i>The Journal of Immunology</i> , 1998,161:5331-5337. (Exhibit 152)
		Whitmire, Jason K., et al., "CD40-CD40 Ligand Costimulation Is Required for Generating Antiviral CD4 T Cell Responses But is Dispensable for CD8 T Cell Responses ¹ ," <i>The Journal of Immunology</i> , 1999,163:3194-3201. (Exhibit 153)
		Bingaman, Adam W., et al., "Vigorous Allograft Rejection in the Absence of Danger ¹ ," <i>Journal of Immunology</i> , 2000,164:3065-3071. (Exhibit 154)
		Bingaman, Adam W., et al., "TRANSPLANTATION OF THE BONE MARROW MICROENVIRONMENT LEADS TO HEMATOPOIETIC CHIMERISM WITHOUT CYTOREDUCTIVE CONDITIONING," <i>Transplantation</i> , 2000, 69:2491-2496. (Exhibit 155)
		Durham, Megan M., et al., "Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoinductive Conditioning ¹ ," <i>Cutting Edge</i> , 2000,165:1-4. (Exhibit 156)
		Williams, Matthew A., et al., "Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts ¹ ," <i>The Journal of Immunology</i> , 2000, 165: 6549-6857. (Exhibit 157)
		Bingaman, Adam W., et al., "The role of CD40L in T cell-dependent nitric oxide production by murine macrophages," <i>Transplant Immunology</i> , 2000, 8:195-202. (Exhibit 158)
		Adams, Andrew B., et al., "Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression ¹ ," <i>The Journal of Immunology</i> , 2001, 167:1103-1111. (Exhibit 159)
		Meng, L., "Blockade of the CD40 Pathway Fails to Prevent CD8 T Cell-Mediated Intestinal Allograft Rejection," <i>Transplantation Proceedings</i> , 2001, 33:418-420. (Exhibit 160)
		Guo, Zhong., et al., "CD8 T CELL-MEDIATED REJECTION OF INTESTINAL ALLOGRAFTS IS RESISTANT TO INHIBITION OF THE CD40/CD154 COSTIMULATORY PATHWAY," <i>Transplantation</i> , 2001, 71:1351-1354. (Exhibit 161)
		Ha, Jongwon., et al., "Aggressive skin allograft rejection in CD28 ^{-/-} mice independent of the CD40/CD40L costimulatory pathway," <i>Transplant Immunology</i> , 2001, 9:13-17. (Exhibit 162)
		Bingaman, Adam W., et al., "ANALYSIS OF THE CD40 AND CD28 PATHWAYS ON ALLOIMMUNE RESPONSES BY CD4 ⁺ T CELLS IN VIVO ¹ ," <i>Transplantation</i> , 2001, 72:1286-1292. (Exhibit 163)
		Adams, Andrew B., et al., "Calcineurin Inhibitor- Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates," <i>Diabetes</i> , 2002, 51:265-270. (Exhibit 164)
		Whelchel, JD., et al. "Evolving Strategies in immunosuppressive Therapy: The Emory Experience," <i>Clinical Transplants</i> , 1996, 20:249-255 (Exhibit 165)
		Ritchie, SC., et al., "Regulation of Immunostimulatory function and B7 molecule expression on murine dendritic cells," <i>Journal of Cellular Biochemistry</i> , 1995,21A:C1-215(Exhibit 166)
212		Alexander, DZ., et al., "Analysis of the mechanisms of CTLA4-Ig plus bone marrow induced transplantation tolerance," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-301 (Exhibit 167)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 11/20/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	



(Use several sheets if necessary)

30436.57USU1

09/865,321

Robert J. Peach et al.

May 23, 2001

1646

712

1

2N

RECEIVED

JUN 19 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

11/20/09

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*

Docket Number

Application Number

30436.57USU1

09/865,321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JTY ²	L104EA29Y (Figure 7, of the subject application) was provided to researchers at Emory University, subject to use restrictions and confidentiality by agreement, more than one year before the priority date of the subject application, i.e. May 26, 2000, for use in animal studies in the U.S.
	L104EA29Y (Figure 7 of the subject application) has been the subject of human clinical trials under the direction and control of Bristol-Myers Squibb Company. L104EA29Y was given to investigators who were involved in the clinical trials subject to use restrictions and confidentiality by agreement. L104EA29Y was administered intravenously to human patients in clinical trials.
	L104EA29Y was first administered intravenously to a human patient as early as November 30, 1998 in Scotland
	L104EA29Y was first administered intravenously to a human patient as early as April 24, 1999 in the United States.
	A letter dated July 9, 1998 including a report, submitted to the U.S. Food and Drug Administration in connection with an Investigational New Drug (IND) application, is enclosed as Exhibit 171.
	The letter and report are confidential and were provided confidentially, pursuant to 21 C.F.R. §20.111 or §21 C.F.R. §312.130, to the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration in connection with the Investigational New Drug Application.
	The enclosed letter and report are redacted versions of what were sent to the U.S. Food and Drug Administration.
	The report contained the sequence for BMS-224818 (Figure 3 at page 13 of Exhibit 171), which differs from CTLA4Ig at two amino acid residues, Leu₁₀₄-Glu and Ala₂₉-Tyr (Exhibit 171 at page 2).
JWL	An Investigator Brochure dated January 26, 1999 is enclosed as Exhibit 172.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900



FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

RECEIVED
JUN 27 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JNR	5,770,197 (Exhibit 182)	June 23, 1998	Peter S. Linsley et al.	X	X	January 22, 1993
	6,132,992 (Exhibit 183)	October 17, 2000	Jeffrey A. Ledbetter et al.			October 5, 1995
	6,090,914 (Exhibit 184)	July 18, 2000	Peter S. Linsley et al.			July 18, 2000
	5,977,318 (Exhibit 185)	November 2, 1999	Peter S. Linsley et al.			June 7, 1995
	5,885,579 (Exhibit 186)	March 23, 1999	Peter S. Linsley et al.			July 8, 1997
	5,993,800 (Exhibit 187)	November 30, 1999	Peter S. Linsley et al.			June 6, 1995
JNR	5,916,560 (Exhibit 188)	June 29, 1999	Christian P. Larsen et al.			March 20, 1997

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JNR	EP 0 613 944 A2 (Exhibit 173)	September 7, 1994	EPO	X	X		X
	EP 0 682 039 A1 (Exhibit 174)	November 15, 1995	EPO				X
	WO 98/56417 (Exhibit 175)	December 17, 1998	PCT				X
	WO 01/92337 (Exhibit 180)	December 6, 2001	PCT				X
JNR	WO 95/34320 (Exhibit 176)	December 21, 1995	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JNR	Sun, Hong et al., "Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody," Transplantation, 1997, 64:1838-56 (Exhibit 177)
JNR	Souza, "Synergistic inhibition of established collagen induced arthritis (CIA) through dual inhibition of ICAM-1 and CD40L pathways," Arthritis and Rheumatism, 1999, page S60; abstract 64 (Exhibit 178)

EXAMINER <i>JNR</i>	DATE CONSIDERED 11/2/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

